Curcumin - From Spice Market to Cancer Laboratory
Few compounds arrive in cancer research carrying as much history, colour and cultural significance as curcumin.
Long before it appeared in laboratory reports and molecular diagrams, turmeric was part of everyday life throughout South Asia. The deep yellow rhizome of Curcuma longa, a plant belonging to the ginger family, was used in food, fabric dyeing, ceremony and traditional systems of medicine. It left its colour on cooking pots, clothing and hands centuries before anyone had named the inflammatory pathways now associated with its biological effects.
Curcumin is one of the pigments responsible for that characteristic golden colour. It belongs to a family of related compounds called curcuminoids, found alongside aromatic oils and many other plant chemicals within the whole turmeric rhizome.
European chemists first isolated the yellow material from turmeric during the early nineteenth century, and its chemical structure was established during the early twentieth century. As scientific methods advanced, researchers began asking a question that traditional use alone could not answer: what, precisely, was curcumin doing inside cells?
The answer proved far less tidy than anyone might have hoped.
Curcumin did not behave like a modern targeted medicine designed to fit one molecular lock. It appeared to interact with a wide range of proteins, enzymes and communication systems. Depending on the model studied, it seemed capable of influencing inflammation, growth signalling, energy sensing, oxidative balance, blood-vessel formation, cell movement and the decision between survival and death.
That breadth is partly why curcumin became so popular in cancer research. Cancer rarely survives through one pathway alone. A tumour may use inflammation to support growth, nutrient signals to continue building, antioxidant systems to contain stress, blood vessels to deliver fuel and repair pathways to recover after treatment. A compound that places pressure across several of those systems is naturally interesting.
It is also why curcumin has become so easy to overstate.
When a compound appears to influence dozens of pathways in a laboratory, it can begin to sound like it does everything. The more sober questions are whether those effects occur at concentrations realistically achievable in the human body, whether an active form reaches the tumour, and whether changing those pathways produces a meaningful clinical outcome.
Curcumin’s story therefore sits between two unhelpful extremes. It is neither a golden cure hidden in a spice jar nor a worthless compound simply because its clinical translation has proved difficult. It is a biologically active substance with compelling mechanistic research, substantial practical limitations and a potentially useful role when placed thoughtfully within a broader strategy.
Turmeric and Curcumin Are Not the Same Intervention
The terms turmeric and curcumin are often used interchangeably, but they describe different things.
Turmeric is the whole rhizome. It contains curcuminoids, aromatic oils, fibre and many other naturally occurring compounds. Curcumin is a concentrated component extracted from that plant material. Using turmeric in food may contribute to a varied, health-supportive diet, but it is not biologically equivalent to using a standardised curcumin preparation.
The difference is similar to the relationship between coffee and isolated caffeine. They are connected, but they do not contain the same substances in the same concentrations, nor should they be expected to produce identical effects.
Even products sold as curcumin are not necessarily comparable. Some contain standard curcuminoid extracts. Others combine curcumin with phospholipids, oils, micelles, nanoparticles or absorption-enhancing compounds. Each delivery system can alter how the compound is absorbed, metabolised and carried through the body.
This matters because curcumin has a fundamental pharmacological weakness: ordinary oral curcumin is poorly absorbed, rapidly changed into other compounds and quickly cleared from the bloodstream.
A large amount swallowed does not necessarily create a large amount of unchanged curcumin in circulation. After passing through the gut, much of it is modified by the intestinal wall and liver before it has any chance of reaching distant tissues. Reviews of curcumin research have repeatedly identified this variable and generally poor bioavailability as a major obstacle to interpreting the literature.
This creates a substantial gap between the laboratory and the human body.
In a cell experiment, researchers can place curcumin directly beside cancer cells at a chosen concentration and leave it there for a defined period. Inside the body, the compound must survive digestion, cross the intestinal barrier, pass through the liver, travel in the blood and enter the tissue where its effects are needed.
Curcumin may possess an impressive laboratory résumé, but the résumé matters far less if the applicant struggles to reach the interview.
This does not mean orally administered curcumin has no biological activity. It may act locally within the digestive tract. Its metabolites may have effects of their own. Some formulations appear to improve measured exposure. But it does mean that formulation is not a trivial detail and that laboratory findings cannot simply be transferred to every capsule carrying the word curcumin.
Cancer Survives Through a Conversation
Cancer is often described as though it were driven by one switch becoming permanently stuck in the “on” position. In reality, it is better understood as an entire conversation inside and around the cell becoming distorted.
Cancer cells continuously receive and send messages. Some tell them that nutrients are available. Others encourage growth, suppress cell death, stimulate inflammation or help repair damage. If one route is blocked, another may compensate. This overlapping communication gives cancer much of its adaptability.
Curcumin has attracted interest because it appears capable of interrupting several parts of this conversation.
Among its most studied targets are NF-κB, STAT3 and PI3K–AKT–mTOR. These names may sound like someone has dropped a bowl of alphabet soup into a pharmacology textbook, but the ideas behind them are relatively straightforward.
NF-κB helps regulate inflammation and cell survival. When activated appropriately, it is part of a normal response to injury or infection. When persistently active within a tumour, it can increase inflammatory signals, anti-death proteins, blood-vessel growth factors and enzymes that help cancer invade surrounding tissues.
STAT3 is another communication system involved in growth, immune activity and survival. Many cancers keep STAT3 signalling active, allowing malignant cells to remain protected and adaptable under difficult conditions.
PI3K–AKT–mTOR is closely involved in nutrient sensing and growth. It helps a cell decide whether enough energy and raw material are available to build proteins, create membranes and divide. In many cancers, this pathway becomes excessively active, continuing to issue instructions for growth even when a healthy cell would slow down.
Curcumin has reduced activity within these networks in numerous preclinical models. Reviews published by the National Cancer Institute and in the scientific literature describe effects on NF-κB, STAT3, PI3K–AKT, mTOR and several related pathways involved in proliferation, survival and resistance.
The value of this broad activity is not that curcumin presses one magical anti-cancer button. It is that it may make the internal conversation supporting cancer less coherent.
The cancer cell may still have access to nutrients. It may still possess growth-promoting mutations. But the signals encouraging it to build, resist death and recover from stress may become less coordinated.
Imagine a construction site where the workers have not disappeared, but the phones keep dropping out, the deliveries arrive late and the building permits are repeatedly delayed. Construction may continue, but it becomes harder to maintain the same pace.
Inflammation and the Environment Cancer Learns to Use
Inflammation is one of the best-known areas of curcumin research, yet it is also one of the most easily oversimplified.
Inflammation is not the enemy. It is part of the body’s normal defence and repair process. When tissue is damaged or infected, inflammatory signals increase blood flow, recruit immune cells and begin healing.
The difficulty arises when inflammation becomes persistent or is recruited into the service of a tumour. Chronic inflammatory signals can encourage cell growth, alter immune behaviour, help build new blood vessels and make surrounding tissue more supportive of invasion. Treatment itself may also trigger inflammatory and survival responses that some cancer cells use to recover.
Curcumin appears capable of reducing parts of this inflammatory communication, particularly through its effects on NF-κB and related inflammatory mediators. Laboratory research has also reported changes in COX-2, tumour necrosis factor and several interleukins.
This does not mean curcumin simply turns inflammation off. Nor would switching off the entire inflammatory system be desirable. The immune system depends on inflammatory activity to recognise danger, repair tissue and respond to infection.
A more accurate description is that curcumin may help turn down some of the chronic, poorly regulated inflammatory signalling that allows a tumour to feel supported.
This is an important reason curcumin fits so naturally within the press side of a Press–Pulse strategy. Its role is not necessarily to create an immediate dramatic response. It is to make the biological background less favourable to continued growth and adaptation.
Making Nutrients Harder to Turn Into Growth
Cancer cells need energy, but their challenge is more complicated than simply finding enough glucose.
A rapidly growing cell must copy DNA, manufacture proteins, construct new membranes and maintain all the internal machinery required for division. To accomplish this, many cancers alter the way they process glucose, fats and amino acids. They also change the signals that decide whether resources should be conserved or invested in growth.
Curcumin has influenced several of these processes in laboratory models. It has been reported to affect glucose uptake, glycolysis, fat production, mitochondrial function and the relationship between AMPK and mTOR.
AMPK can be thought of as an internal low-fuel warning system. When usable energy becomes scarce, AMPK encourages the cell to conserve resources, repair damage and slow growth.
mTOR delivers a different message. When nutrients and growth signals appear abundant, mTOR gives the cell permission to build.
Preclinical studies suggest curcumin can increase energy-stress signalling while reducing parts of the mTOR growth programme. Its effects on PI3K–AKT further connect curcumin with the way cancer cells interpret nutrient and growth signals.
Curcumin does not remove glucose from the bloodstream in the way that fasting or dietary change may alter nutrient availability. Instead, it may interfere with the cancer cell’s ability to convert available nutrients into continued growth.
It does not necessarily take the meal away. It may make the kitchen less efficient.
This distinction helps clarify curcumin’s place in metabolic oncology. Its role is not simply “anti-inflammatory support” or “antioxidant protection.” It may also place pressure on how cancer cells sense, process and respond to the resources around them.
Mitochondria and the Cell’s Exit Door
Mitochondria are commonly described as the power stations of the cell, but they are also deeply involved in redox balance, nutrient processing and the decision about whether a badly damaged cell should survive.
In several cancer models, curcumin has disturbed the electrical balance across the mitochondrial membrane. When that membrane becomes unstable, energy production may fall and death-signalling molecules can be released into the surrounding cell.
This can contribute to apoptosis, the organised form of cell death used by healthy tissues to remove cells that are damaged beyond safe repair.
Cancer cells frequently develop ways to resist apoptosis. They may increase proteins that protect them from death, disable internal safety systems or ignore signals that would cause a healthy cell to withdraw.
Curcumin has been reported to reduce anti-death signalling and increase pro-death pathways in laboratory studies. These effects often involve the mitochondria, oxidative stress and proteins responsible for deciding whether the cell continues or shuts itself down. The NCI summary describes evidence that curcumin can inhibit proliferation and promote apoptosis across a range of experimental cancer models.
This is an important conceptual point because cancer is not only a disease of excessive growth. It is also a disease of insufficient death.
Curcumin may help restore some of the biological pressure telling a severely damaged cell that it should no longer continue.
Whether this occurs at meaningful levels within a human tumour depends heavily on exposure and formulation, but the mechanism helps explain why curcumin has remained such a persistent subject of oncology research.
Antioxidant, Pro-Oxidant—or Both?
Curcumin is widely described as an antioxidant. That description is not wrong, but it is incomplete.
In some settings, curcumin can reduce oxidative injury and influence the body’s antioxidant response. In others, particularly in experimental cancer cells, it may increase reactive oxygen species, disturb mitochondria and contribute to oxidative stress severe enough to promote cell death.
This apparent contradiction is common in redox biology.
The effect of a compound can change according to concentration, cell type, mitochondrial health, metal availability, antioxidant capacity and the level of oxidative stress already present.
Many cancer cells operate with a higher baseline level of oxidative stress than healthy cells. Their rapid growth and altered metabolism produce reactive molecules, requiring them to maintain strong antioxidant defences. A further oxidative challenge may therefore affect a malignant cell differently from a healthy cell with greater spare capacity.
Curcumin may sometimes help calm excessive oxidative and inflammatory injury in normal tissues while adding stress within a susceptible cancer cell. However, it would be too simplistic to claim that it always protects healthy cells and selectively kills cancer. Its behaviour is conditional, and much of the evidence remains experimental.
This is especially important when curcumin is considered around radiotherapy or chemotherapy. It should not be labelled simply as an antioxidant and then included or excluded on that basis. The relevant questions are what treatment is being used, what biological effect is intended, which formulation is being considered and when the compound would be used.
Blood Vessels, Invasion and Cancer’s Ability to Move
A tumour can only grow so far without developing a better supply network.
It needs oxygen, glucose, amino acids and a way of removing waste. To overcome these limitations, tumours can release signals that encourage new blood vessels to grow towards them. This process is called angiogenesis.
Curcumin has reduced vascular endothelial growth factor, or VEGF, and other angiogenic signals in preclinical research. It has also influenced enzymes and pathways involved in breaking down surrounding tissue and allowing cancer cells to move.
This matters because metastasis is not a single leap from one organ to another. It is a difficult sequence of events. A cancer cell must detach from the original tumour, alter its behaviour, invade surrounding tissue, enter the circulation, survive the journey, leave the bloodstream and establish itself in a new location.
Curcumin has been investigated for effects on several parts of this process, including cell adhesion, matrix-degrading enzymes and epithelial–mesenchymal transition, a change that can make some cancer cells more mobile and adaptable.
These findings do not demonstrate that taking curcumin prevents metastasis in people. They do suggest that the compound can influence some of the biological behaviours involved in tumour spread, adding another layer to its proposed role as a sustained press.
The Cells Capable of Starting Again
One of the most important questions after treatment is not only how much tumour has disappeared, but which cells remain.
Within many cancers are populations with stem-like characteristics. These cells may be more capable of self-renewal, adapting to stress, resisting treatment and rebuilding the tumour after much of the visible disease has been removed.
The phrase cancer stem cell can make these cells sound like one permanent and easily identifiable group. In reality, stem-like behaviour can be fluid. Cancer cells may gain or lose these characteristics in response to treatment, inflammation and their surrounding environment.
Even with that complexity, the concept remains clinically important. A treatment may shrink the majority of a tumour while leaving behind a smaller population with greater capacity to regenerate it.
Curcumin has been investigated for effects on pathways associated with stem-like behaviour, including Wnt/β-catenin, Notch, Hedgehog, STAT3 and the Hippo pathway. Reviews and laboratory studies have reported reduced stem-like signalling, tumour-sphere formation and resistance in several experimental cancer models.
This area is especially relevant when thinking about recurrence and microscopic remission. Reducing visible tumour burden is essential, but long-term control may also depend on what treatment-resistant populations survive.
Curcumin cannot honestly be described as a proven cancer stem-cell eliminator. The evidence is predominantly preclinical, the relevant markers vary between cancers and stem-like behaviour is more complex than one pathway.
What can be said is that curcumin appears capable of influencing several signalling networks associated with tumour regeneration and treatment resistance. That gives it a rational place in research concerned not only with shrinking the tumour, but with making it less capable of rebuilding.
Curcumin as a Treatment Sensitiser
Cancer cells do not remain passive while treatment damages them.
Following chemotherapy or radiotherapy, surviving cells may activate repair mechanisms, inflammatory pathways, antioxidant systems and anti-death signals. They attempt to recover, much as a city begins repairing roads and restoring electricity after a storm.
Curcumin has been investigated as a sensitiser because it may interfere with parts of this recovery response.
By placing pressure on NF-κB, STAT3, PI3K–AKT and other survival pathways, curcumin may make a damaged cancer cell less capable of restoring stability. Reviews of curcumin combined with chemotherapy describe experimental effects on multidrug resistance, apoptosis, drug transport and several treatment-survival pathways.
Curcumin has also been explored alongside radiotherapy. Preclinical research suggests it may sensitise some cancer cells to radiation while potentially reducing certain inflammatory effects in normal tissues, although the balance between radiosensitisation and radioprotection is complex and remains dependent on the biological setting.
This dual possibility is interesting, but it is not permission to add curcumin indiscriminately to every treatment plan.
A sensitiser must be used intelligently. Making the tumour more vulnerable may be desirable; unexpectedly altering drug exposure or increasing damage to healthy tissue is not. Curcumin may influence metabolic enzymes, transport proteins, platelet activity and redox balance, all of which could become relevant during oncology treatment.
The useful question is therefore not whether curcumin is “good with chemotherapy.” It is which chemotherapy, which cancer, which formulation, at what point in the cycle and for what intended purpose.
Without that level of consideration, integration becomes little more than guesswork wearing a lab coat.
Where Curcumin Fits Within Press–Pulse
Within a Press–Pulse strategy, curcumin fits most naturally within the sustained press.
Its proposed value lies in applying ongoing pressure to several systems that help cancer remain supported and adaptable: chronic inflammatory signalling, growth and nutrient-sensing pathways, mitochondrial stability, angiogenesis, invasion and stem-like behaviour.
Curcumin is not usually the battering ram striking the tumour’s front gate. It is better understood as an intervention interfering with the supply lines, weakening communication and making the repair crews less efficient before stronger pressure arrives.
This distinction matters because not every part of a coordinated strategy needs to perform the same job.
One intervention may reduce the availability of a fuel. Another may change insulin signalling. Another may influence immune recognition. Another may create acute oxidative stress or directly damage DNA.
Curcumin’s role may be to make the cancer cell less comfortable and less capable of adapting to all of those pressures.
Its laboratory effects on apoptosis, mitochondria and oxidative stress show that it can have direct anti-cancer activity under experimental conditions. But its most credible conceptual place in a broader strategy is as a press compound with sensitising potential.
It may help shape the conditions into which a pulse is delivered.
When inflammatory rescue pathways are quieter, growth signalling is less active and repair mechanisms are already under pressure, chemotherapy, radiotherapy, hyperthermia or another pulse may become more difficult for the cancer cell to survive.
That does not make curcumin the centre of the strategy. It gives it a defined supporting role within one.
The Bioavailability Problem Cannot Be Wished Away
Curcumin’s scientific reputation has often been built on what it can do when placed directly beside cancer cells.
Its clinical challenge is getting enough active compound to the right place inside the body.
Ordinary curcumin dissolves poorly in water, is absorbed inefficiently and is rapidly converted into metabolites. Different formulations can create dramatically different measurements in blood, yet reviews have found that curcumin studies and even systematic reviews often fail to account adequately for those differences.
This makes formulation part of the intervention itself.
A phospholipid complex is not automatically equivalent to a micellar preparation. A nanoparticle product is not automatically equivalent to curcumin combined with piperine. Each may produce different forms of the compound, at different concentrations, for different periods.
Even improved absorption does not settle the issue. A product may increase total curcumin-related material in the bloodstream without proving that enough active curcumin reaches the tumour to reproduce the effects seen in laboratory studies.
The bioavailability problem therefore should not be treated as a brief caveat placed near the end of the article. It is central to understanding why curcumin can look so powerful on paper while producing far less dramatic evidence in clinical practice.
A compound can have excellent biological ideas and still struggle with delivery.
The best map in the world is little help if the vehicle cannot reach the destination.
What Human Research Actually Shows
Curcumin has been explored in clinical studies involving several cancers, including colorectal, pancreatic, prostate, breast and blood cancers. Researchers have investigated biological markers, symptoms, tolerability, treatment-related effects and combinations with conventional therapy.
Some studies have reported changes suggesting biological activity. Others have observed possible effects on symptoms or treatment tolerance. However, many trials have been small, used different formulations, included different stages of disease or focused on laboratory markers rather than survival and long-term tumour control.
This makes the human evidence difficult to combine into one clear conclusion.
The National Cancer Institute continues to classify curcumin as investigational. It has not been approved as a treatment for cancer, and the current evidence does not establish it as a replacement for surgery, radiotherapy, chemotherapy, immunotherapy, hormonal therapy or targeted treatment.
The evidence is best understood in layers.
The mechanistic evidence is extensive. Curcumin can influence many pathways relevant to cancer biology.
The preclinical evidence is substantial. It has repeatedly affected cultured cancer cells and animal tumour models.
The clinical evidence remains limited. It has not yet shown that curcumin consistently improves survival or long-term cancer control across well-designed, large clinical trials.
That hierarchy does not make curcumin irrelevant. It tells us how confidently we can speak about it.
There is enough evidence to take the compound seriously. There is not enough to turn it into a promise.
Why Curcumin Still Deserves Attention
Curcumin has become trapped between enthusiasm and cynicism.
One side presents it as a natural answer to almost every disease. The other points to poor absorption and inconsistent clinical evidence and concludes that the entire subject is unworthy of attention.
Neither response does justice to the science.
Curcumin matters because cancer is a networked disease. Tumours survive through cooperation between inflammation, nutrient signalling, mitochondrial adaptation, blood-vessel growth, repair pathways and resistant cell populations.
Curcumin appears capable of placing moderate pressure across several of those systems.
That may not be enough to produce dramatic tumour regression by itself. Its value may instead lie in making the tumour less resilient when stronger treatment arrives.
A coordinated cancer strategy is less like searching for one heroic player and more like disrupting an opposing team. It may be difficult to win while the other side retains perfect communication, fresh defenders, clear passing lanes and unlimited substitutes.
Curcumin may not score the decisive goal. Its possible contribution is to disrupt the midfield, slow the supply of opportunities and make recovery more difficult when decisive pressure is applied elsewhere.
That is a less glamorous claim than calling it a natural cancer cure.
It is also far more credible.
Clinical Perspective and Important Boundaries
Curcumin is widely available, but availability does not mean it is universally appropriate.
Concentrated curcumin may influence platelet activity and bleeding risk. It may aggravate gallbladder or bile-duct problems, contribute to gastrointestinal symptoms and interact with medicines through enzymes or transport proteins involved in drug metabolism.
Absorption enhancers introduce further complexity. Piperine may increase curcumin exposure, but it can also affect how prescription medicines are absorbed and processed.
This becomes particularly important during chemotherapy, targeted therapy, immunotherapy, anticoagulant treatment and the use of medicines with narrow safety margins.
Curcumin’s redox behaviour also means timing deserves careful thought. Labelling it simply as an antioxidant may lead to inappropriate assumptions about whether it should be used around treatments that rely partly on oxidative damage.
The correct decision depends on the diagnosis, treatment, formulation, intended purpose and wider protocol.
Curcumin should not replace evidence-based oncology care. Its most credible role is as a biologically active adjunct considered within a coordinated strategy and guided by practitioners who understand both metabolic oncology and the conventional treatment plan.
Curcumin is far more interesting than its popular image as the yellow ingredient in turmeric drinks suggests.
It is a multi-target compound capable of influencing inflammation, growth and nutrient signalling, mitochondrial function, angiogenesis, invasion, treatment resistance and pathways associated with stem-like cancer cells.
Its most natural place within metabolic oncology is as part of the sustained press.
Rather than relying upon one dramatic strike, curcumin may help make the biological environment less supportive of tumour growth while narrowing some of the routes cancer cells use to adapt and recover. It may also have sensitising value, allowing stronger therapeutic pulses to arrive when the cancer cell’s survival systems are already under greater strain.
Curcumin is not a miracle compound. Poor absorption, rapid metabolism, variable formulations and limited clinical evidence remain genuine constraints. The striking effects seen in laboratory models cannot simply be assumed to occur inside a human tumour after taking an ordinary supplement.
Those limitations should protect us from exaggeration, but they should not prevent thoughtful consideration.
Cancer often survives through redundancy. When one pathway is blocked, another may take over. Curcumin’s possible value lies in its ability to apply pressure across more than one of those routes.
Its role may not be to destroy the tumour in a single golden blow. It may be to make the road ahead narrower, the repair process slower and the wider therapeutic strategy harder for cancer to escape.
That is where curcumin earns its place in metabolic oncology: not as a cure hiding in a spice jar, but as one carefully selected compound performing a defined role within a coordinated plan.
Important Disclaimer
This article is provided for educational and informational purposes only. It is intended to help you understand the research and proposed role of curcumin within a broader metabolic oncology strategy. It is not medical advice and should not be used to diagnose cancer, select treatment, prescribe supplements or alter an existing oncology plan.
Curcumin is biologically active, and available formulations vary considerably in absorption, strength and interaction potential. Its suitability depends on factors including the cancer type, stage of disease, current treatment, medications, clotting risk, liver and gallbladder health, gastrointestinal function and the intended purpose of the compound within the wider strategy.
Do not begin, stop or change curcumin, medication, supplementation or cancer treatment based on this article alone. The use of concentrated curcumin during cancer care should be discussed with the treating oncology team and guided by a qualified and experienced practitioner in metabolic oncology who can assess your individual circumstances and coordinate its use safely.
The research discussed includes laboratory, animal and human evidence. These forms of evidence are not equivalent, and promising mechanisms do not guarantee benefit in an individual situation.
References
National Cancer Institute. Curcumin and Cancer (PDQ®): Health Professional Version. Updated May 13, 2025.
National Cancer Institute. Curcumin and Cancer (PDQ®): Patient Version. Updated May 28, 2024.
Hewlings SJ, Kalman DS. Curcumin: A review of its effects on human health. Foods. 2017;6(10):92. doi:10.3390/foods6100092.
Zoi V, Galani V, Tsekeris P, Kyritsis AP, Alexiou GA. The role of curcumin in cancer: a focus on the PI3K/Akt pathway. International Journal of Molecular Sciences. 2024;25(8):4307. PMID: 38672636.
Popović VB, et al. Bioavailability of oral curcumin in systematic reviews: a methodological study. Nutrients. 2024;16(4):501. doi:10.3390/nu16040501.
Norris L, Karmokar A, Howells L, Steward WP, Gescher A, Brown K. The role of cancer stem cells in the anti-carcinogenicity of curcumin. Molecular Nutrition & Food Research. 2013. PMID: 23900994.
Zheng Y, et al. Curcumin suppresses the stemness of non-small-cell lung cancer cells through promoting the nuclear-cytoplasm translocation of TAZ. Environmental Toxicology. 2021. PMID: 33539684.
Sordillo PP, Helson L. Curcumin and cancer stem cells: curcumin has asymmetrical effects on cancer and normal stem cells. Anticancer Research. 2015;35(2):599–614. PMID: 25667437.
Tan BL, Norhaizan ME. Curcumin combination chemotherapy: the implication and efficacy in cancer. Molecules. 2019;24(14):2527. doi:10.3390/molecules24142527.
Saha S, Adhikary A, Bhattacharyya P, Das T, Sa G. Death by design: where curcumin sensitizes drug-resistant tumours. Anticancer Research. 2012;32(7):2567–2584. PMID: 22753715.
Zoi V, Galani V, et al. Radiosensitization and radioprotection by curcumin in cancer treatment. Biomedicines. 2022;10(2):312. doi:10.3390/biomedicines10020312.